Regio

Regio Biosciences Enters into License Agreement with AstraZeneca for Phase 2a Asset in Peripheral Artery Disease (PAD)

Retrieved on: 
Thursday, February 3, 2022
Science, Cardiology, Other Science, Biotechnology, Research, Health, Clinical Trials, Other Health, Disease, CEO, Patient, Mortality, LDL, Health, List of life sciences, Plaque, RCT, Research, CPC, Walking, Executive, CDC, Peripheral artery disease, Cardiovascular disease, Gangrene, HCM, PAD, AstraZeneca, Pain, CSO, Blood pressure, Drug development, Multimedia, Amputation, Hope, Hibiscus, Pharmaceutical industry, Regio, MD, Regio Biosciences, Hibiscus BioVentures, REGIO BIOSCIENCES, HIBISCUS BIOVENTURES

Regio expects to initiate a Phase 2a clinical program evaluating REG-101 in PAD during the second half of 2022.

Key Points: 
  • Regio expects to initiate a Phase 2a clinical program evaluating REG-101 in PAD during the second half of 2022.
  • The Regio team is thrilled to announce the signing of this license agreement with AstraZeneca to further develop REG-101, said Chris Jeffers, Chairman of Regio Biosciences and CEO of Hibiscus BioTechnology.
  • We believe that REG-101 could complement the current standard of care as a patient-centric, once-monthly injection for peripheral artery disease.
  • Regio has partnered with CPC Clinical Research (CPC) and multiple clinical sites in the US to conduct a Phase 2a clinical trial in patients with peripheral artery disease.

Essity presents new business areas and new sales growth target

Retrieved on: 
Friday, October 22, 2021
Pharmacy, Libero, Growth, Technology, Rising Medical Solutions, Hospital, Hand, Elective surgery, Tork, Medicine, Child, Final good, Internet, Maintenance, Personal care, Tempo, Restaurant, Regio, Incontinence, Lotus, Healthcare Facilities Accreditation Program, Pro forma, Acquisition, University, Mon Health Medical Center, The Things, TENA, Risk management, Tissue paper

As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.

Key Points: 
  • As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.
  • The new areas support the company's new growth target through strategies for organic and acquisition-driven growth and aim to achieve higher growth and profit margins as well as less capital tied up.
  • The business areas will replace the current business areas Personal Care, Consumer Tissue and Professional Hygiene.
  • The new growth target is to achieve sales growth of more than 5%.

Essity presents new business areas and new sales growth target

Retrieved on: 
Friday, October 22, 2021
Pharmacy, Libero, Growth, Technology, Rising Medical Solutions, Hospital, Hand, Elective surgery, Tork, Medicine, Child, Final good, Internet, Maintenance, Personal care, Tempo, Restaurant, Regio, Incontinence, Lotus, Healthcare Facilities Accreditation Program, Pro forma, Acquisition, University, Mon Health Medical Center, The Things, TENA, Risk management, Tissue paper

As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.

Key Points: 
  • As a consequence of its higher growth ambitions, Essity has also decided on a new sales growth target of more than 5%, which includes both organic sales growth and acquisitions.
  • The new areas support the company's new growth target through strategies for organic and acquisition-driven growth and aim to achieve higher growth and profit margins as well as less capital tied up.
  • The business areas will replace the current business areas Personal Care, Consumer Tissue and Professional Hygiene.
  • The new growth target is to achieve sales growth of more than 5%.